Full text is available at the source.
Abstract
Semaglutide initiation may be associated with modified 3-point major adverse cardiovascular events (MACE) among obesity-related cancer survivors with type 2 diabetes.
- Obesity-related cancer survivors often face unique health challenges and are typically excluded from major clinical trials.
- The cardiovascular risks in this population are significant, warranting further investigation into effective treatments.
- Semaglutide is a type of GLP-1 receptor agonist that may offer benefits for managing type 2 diabetes.
- Comparison with other GLP-1 receptor agonists could provide insights into cardiovascular outcomes in this specific group.
Simplified